The expression and clinical significance of YAP and cIAP1 in ovarian serous adenocarcinoma

摘要

Objective: To investigate the expression and clinical significance of yes-associate protein (YAP) and cellular inhibitor of apoptosis of protein-1 (cIAP1) in ovarian serous adenocarcinoma. Materials and Methods: The expression of YAP and cIAP1 were detected by immunohistochemistry (IHC) in 62 ovarian tumor tissues. The association of YAP, cIAP1, clinical pathological characteristics in patients, and the prognosis were further analyzed. Results: Among 62 ovarian serous adenocarcinoma tissues obtained from the patients, the positive and the strong positive rate of YAP in patients with tumor tissues were significantly higher than normal tissues. Similar results were found for cIAP1. Moreover, YAP expression was correlated to cIAP1 expression. Furthermore, the expression of YAP and cIAP1 was significantly related to the low tumor differentiation, recurrence, and platinum resistance. Uni-variable analysis showed that YAP expression, FIGO Stage, lymphatic metastasis, ascites as initiating symptom, and the platinum resistance were factors affecting progression-free survival (PFS) of patients. On the other hand, the overall survival rate (OS) was affected by YAP and cIAP1 expression, age, FIGO Stage, recurrence, and platinum resistance. The multi-variable analysis demonstrated that resistance to the initial platinum therapy and the expression of YAP were independent prognosis factors that affected the postoperative OS in ovarian serous adenocarcinoma. The co-expression of YAP and cIAP1 were negatively associated with postoperative PFS and OS in ovarian serous adenocarcinoma patients. Conclusion: YAP and cIAP1 may be relevant to the initiation and growth of the ovarian serous adenocarcinoma and they may serve as negative prognosis factor for ovarian serous adenocarcinoma prognosis.